Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060253 | 0.85 | ACE (0.59) | MMP3ACENPC1RAB9AMMP2 | |
| SCHEMBL10078882 | 0.85 | TSHR (0.65) | SMN1; SMN2KMT2AMEN1HTTHPGD | |
| SCHEMBL23616381 | 0.85 | TSHR (0.65) | SMN1; SMN2KMT2AMEN1HTTHPGD | |
| SCHEMBL21040564 | 0.81 | CPA1 (0.57) | SMN1; SMN2KMT2AMEN1HTTHPGD | |
| SCHEMBL23616270 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AMEN1HTTHPGD | |
| SCHEMBL26646315 | 0.77 | MMP1 (0.55) | MMP3ALDH1A1MMP2 | |
| SCHEMBL584516 | 0.76 | TSHR (0.54) | SMN1; SMN2KMT2AMEN1HTTHPGD | |
| SCHEMBL14338210 | 0.75 | SMN1; SMN2 (0.69) | SMN1; SMN2KMT2AMEN1HTTHPGD | |
| SCHEMBL23616296 | 0.75 | CTSS (0.67) | — | |
| SCHEMBL23616295 | 0.75 | CTSS (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163792-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | SMN1; SMN2 2452/4885KMT2A 3594/4885MEN1 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.